Scientists have discovered how interactions between RNA and the TOP1 essential enzyme, which is overexpressed in many human cancers, regulate DNA during transcription and may inform the creation of new cancer therapies, according ...
Aug 22, 2024
0
26
A new research perspective published in Oncoscienceexplores SLFN11's surveillance role in protein homeostasis.
Aug 3, 2022
0
6
New insights into the mechanisms behind how cancer-causing agents in the environment activate genetic recombination in DNA could help to explain some of the effects of exposure as well as predicting which individuals may ...
Nov 17, 2020
0
62
An international team of researchers has shown why a standard treatment for the aggressive blood-cell cancer AML so often fails. The study uncovers a new biomarker that predicts the efficacy of the chemotherapy and identifies ...
Dec 20, 2016
0
0
A novel two-pronged strategy targeting DNA synthesis can treat leukemia in mice, according to a study in The Journal of Experimental Medicine.
Feb 24, 2014
0
0
Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point.
Jun 18, 2013
0
0
Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but ...
Apr 15, 2013
0
1
Like any factory, the body burns oxygen to get energy for its various needs. As a result, detrimental byproducts are released and our cells try to clean up shop with antioxidants. But as we age, this process becomes a losing battle.
Mar 4, 2013
0
0
A three molecule complex may be a target for treating Huntington's disease, a genetic disorder affecting the brain. This finding by an international research team including scientists from the German Center for Neurodegenerative ...
Feb 26, 2013
0
0
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Dec 9, 2012
0
0
